Clinical trials: Dyslipidemias
Lipid Metabolism, Inborn Errors, Hypercholesterolemia, Autosomal Dominant
An Open-label Extension Study to Assess the Long-term Safety and Efficacy of ISIS 301012 (Mipomersen) in Patients With Familial Hypercholesterolemia or Severe-Hypercholesterolemia
To evaluate the safety and efficacy of extended dosing with mipomersen (ISIS 301012) in participants with familial hypercholesterolemia or severe hypercholesterolemia on lipid-lowering therapy who had completed either the…
- Conditions
- Lipid Metabolism, Inborn Errors, Hypercholesterolemia, Autosomal Dominant, Hyperlipidemias, Metabolic Diseases
- Trial name
- NCT00694109
- Testing
- Mipomersen Sodium
- Where
- 33 sites in United States, Brazil and 5 more
- Volunteers
- 144 people
- Sponsor
- Kastle Therapeutics, LLC
Metabolic Diseases, Hyperlipidemias
Safety and Efficacy Study of ISIS 301012 (Mipomersen) Administration in High Risk Statin Intolerant Subjects
The purpose of this study is to determine safety and efficacy of mipomersen (ISIS 301012) in the reduction of total cholesterol, low density lipoprotein cholesterol (LDL-C), and apolipoprotein B (apoB) in high risk subjects…
- Conditions
- Metabolic Diseases, Hyperlipidemias, Metabolic Disorder, Hypercholesterolemia
- Trial name
- ASSIST (NCT00707746)
- Testing
- mipomersen
- Where
- Netherlands
- Volunteers
- 34 people
- Sponsor
- Kastle Therapeutics, LLC
Severe Hypertriglyceridemia
Epanova® for Lowering Very High Triglycerides
The primary objective of the study is to determine the efficacy of Epanova (omefas) compared to placebo in lowering serum triglycerides in subjects with severe hypertriglyceridemia.
- Trial name
- EVOLVE (NCT01242527)
- Testing
- omefas
- Where
- 68 sites in United States, Denmark and 5 more
- Volunteers
- 399 people
- Sponsor
- AstraZeneca
Dyslipidemia, Hypercholesterolemia
Pilot Study To Assess CAT-2003 in Patients With Hyperlipidemia
The purpose of this study is to determine the safety and efficacy of different doses of CAT-2003 in patients with hyperlipidemia when CAT-2003 is taken for 4 weeks.
- Conditions
- Dyslipidemia, Hypercholesterolemia, Hypertriglyceridemia
- Trial name
- PATHWAYS I (NCT01912560)
- Testing
- CAT-2003, Statin
- Where
- 14 sites in United States, Canada
- Volunteers
- 99 people
- Sponsor
- Catabasis Pharmaceuticals
Dyslipidemia
A Clinical Trial to Compare Safety and Pharmacokinetic Characteristics of CKD-337
This study is a randomized, open-label, single oral dose, 2-way crossover clinical trial to compare safety and pharmacokinetics of CKD-337 in healthy male volunteers.
- Trial name
- NCT02651753
- Testing
- Lipitor + Lipidil supra, CKD-337
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Diabetes Mellitus
Efficacy of SYR-472 in Subjects With Type 2 Diabetes Mellitus
The purpose of this study is to determine the efficacy, safety and tolerability of SYR-472, once daily (QD), in subjects with Type 2 Diabetes Mellitus.
- Trial name
- NCT00653185
- Testing
- SYR-472
- Where
- 87 sites in United States, Chile and 10 more
- Volunteers
- 369 people
- Sponsor
- Takeda
Diabetes Mellitus
Efficacy and Safety of TAK-379 in Adult Subjects With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the safety and effectiveness of multiple doses of TAK-379, once daily (QD), in subjects with type 2 diabetes mellitus.
- Trial name
- NCT00722917
- Testing
- TAK-379, Pioglitazone
- Where
- 8 sites in United States
- Volunteers
- 323 people
- Sponsor
- Takeda
Diabetes Mellitus
Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus
The purpose of this study is to determine the efficacy and safety of SYR-472, once daily (QD), in subjects with type 2 diabetes mellitus who have not achieved glycemic control with diet and exercise, or by taking metformin.
- Trial name
- NCT00760344
- Testing
- SYR-472, Sitagliptin
- Where
- 112 sites in United States, Mexico
- Volunteers
- 386 people
- Sponsor
- Takeda
Essential Hypertension With Stable Angina and Dyslipidemia
A Study to Evaluate the Effects of Azilsartan on Coronary Artery Plaque in Essential Hypertensive Patients With Stable Angina and Dyslipidemia.
The purpose of this study is to evaluate the effects of oral azilsartan once daily for 32 weeks on coronary artery plaque in essential hypertensive patients with stable angina and dyslipidemia.
- Trial name
- ALIVE (NCT02400775)
- Testing
- Azilsartan
- Where
- Japan
- Sponsor
- Takeda
Hypercholesterolemia, Dyslipidemia
Atorvastatin Study in Cardiovascular Disease Risk
Treatment of hypercholesterolemia is based on the guidelines of ESC-EAS 2011 (European Heart Journal (2011) 32, 1769-1818, ESC / EAS Guidelines for the management of dyslipidaemias) These calculate the 10 year risk based on SCORE…
- Trial name
- ANTLER (NCT02392416)
- Where
- 2 sites in Greece
- Volunteers
- 900 people
- Sponsor
- Elpen Pharmaceutical Co. Inc.
Dyslipidaemia
CEntralized Pan-Russian Survey of tHE Undertreatment of hypercholeSterolemia II (CEPHEUS II)
This is a multi-center survey of patients who are currently receiving lipid-lowering medications and have a moderate or higher cardiovascular (CV) risk. The survey will be conducted in the Russian Federation.
- Trial name
- CEPHEUSII (NCT02230241)
- Where
- 27 sites in Russia
- Volunteers
- 2,700 people
- Sponsor
- AstraZeneca
Dyslipidemia
Compare the Pharmacokinetics of NVP-1205 and Coadministration of Rosuvastatin and Ezetimibe
The purpose of this study is to compare the pharmacokinetics of NVP-1205 and coadministration of rosuvastatin and ezetimibe.
- Trial name
- NVP-1205 (NCT02029625)
- Testing
- NVP-1205, rosuvastatin and ezetimibe
- Where
- South Korea
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- NVP Healthcare
Dyslipidemia
Evaluation of Absorption, Metabolism, and Excretion and Estimation of the Absolute Bioavailability of K-312
The purpose of this study is to Evaluation of absorption, metabolism, and excretion of [14C]-K-312 and estimation of the absolute bioavailability of K-312 in healthy male subjects
- Trial name
- NCT02676830
- Testing
- K-312 100 mg, K-312 100 ug C14 IV
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Kowa Research Institute, Inc.
Dyslipidaemia
Bioequivalence Study of Capsule and Tablet Formulations of TA-8995
The purpose of this study is to compare the pharmacokinetics of capsule and tablet formulations of TA-8995 in healthy male subjects aged 18 to 55 years.
- Trial name
- NCT02523391
- Testing
- TA-8995
- Where
- United Kingdom
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Xention Ltd
Dyslipidemia
Study to Assess PK/PD Character, Safety/Tolerability of CKD-519 New Formulation in Healthy Male Subject.
Study to assess the pharmacokinetic/pharmacodynamic characteristics and safety/tolerability to CKD-519 new formulation in healthy male subjects.
- Trial name
- NCT02623868
- Testing
- CKD-519 50mg 2Tabs., CKD-519 100mg 1Tab., CKD-519 100mg 1Cap.
- Where
- South Korea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Hyperlipidemia or Mixed Dyslipidemia at High Risk for Cardiovascular Events
Study of Low-Density Lipoprotein Cholesterol (LDL-C) Reduction Using Evolocumab (AMG 145) in Japanese Patients With Advanced Cardiovascular Risk
The primary objective of the study was to evaluate the effect of 12 weeks of subcutaneous evolocumab administered every 2 weeks and once a month, compared with placebo, on percent change from baseline in LDL-C when used in…
- Trial name
- AMG145 (NCT01953328)
- Testing
- Atorvastatin, Evolocumab
- Where
- 54 sites in Japan
- Volunteers
- 409 people
- Sponsor
- Amgen
Dyslipidemia
A Study to Evaluate MK1903 in Patients With Dyslipidemia (MK1903-004)
This study will evaluate the lipid-modifying effect and tolerability of MK1903 when compared to placebo in patients with dyslipidemia who are not on a statin or other lipid-modifying therapy.
- Trial name
- NCT00847197
- Testing
- MK1903
- Volunteers
- 191 people
- Sponsor
- Merck Sharp & Dohme LLC
Hypercholesterolemia, Hyperlipidemias
Lipid-lowering Effect of Plant Stanol Ester Yoghurt Drinks
The aim is to investigate the effects of yoghurt drinks containing two doses of plant stanol ester either with or without added camelina oil on the serum cholesterol levels in moderately hypercholesterolemic subjects
- Conditions
- Hypercholesterolemia, Hyperlipidemias, Dyslipidemias
- Trial name
- NCT02628990
- Testing
- 1.6 g plant stanols, 2 g plant stanols, 1.6 g plant stanols and camelina oil
- Volunteers
- 155 people, healthy volunteers welcome
- Sponsor
- Raisio Group
Dyslipidemia
Study to Investigate the Effect of Food on the Pharmacokinetics/Pharmacodynamics and Safety of CKD-519(CKD-519 FDI)
The purpose this study investigate the effect of food on the pharmacokinetics/pharmacodynamics and safety of CKD-519
- Trial name
- NCT02484482
- Testing
- CKD-519 200mg / Fasting, Standard Meal, High Fat Meal
- Where
- South Korea
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Primary Dyslipidemia
Effect of a Low Fat Milk Product on Lipids Profile in Dyslipidemia Subjects
The aim of LipiDown (Hawthorn + Phytosterol) clinical trial is to test the blood lipids reduction effect of plant sterols and hawthorn in milk powder in a pilot human trial: demonstrate potential to reduce total blood cholesterol…
- Trial name
- Lipidown (NCT02221973)
- Testing
- sterols and hawthorn powder
- Where
- 3 sites in China
- Volunteers
- 75 people
- Sponsor
- Société des Produits Nestlé (SPN)